Phase 2 N=69 CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Clear Cell Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.91; 3.81 months — p=0.07905
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=156 A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs — 24; 21; 22; 6 Participants
Phase 2 N=40 The Effects of Cannabidiol on the Driving Ability of Healthy Adults
Driving Performance · Cognitive Impairment · Sedation Complication
Primary: Driving Performance - Percent of Time Spent Out of Lane — 4.41; 4.34 Percent time spent driving out of lane — p=0.9460
Phase 2 N=267 Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
Current or Recent History of Atrial Fibrillation
Primary: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of…
Phase 2 N=196 A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure With Preserved Ejection Fraction
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Study Drug-related TEAEs — 61; 4; 6; 72 Participants
Phase 2 N=34 Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair
Postsurgical Pain
Primary: Pain at Rest - Part B — 148.98; 188.26 score on a scale*hours — p=0.4812
Phase 2 N=27 OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis
Exocrine Pancreatic Insufficiency (EPI) · Cystic Fibrosis (CF)
Primary: Safety of MS1819 by Number of Subjects Reporting 1 or More Adverse Events — 1; 0; 2; 0 Participants
Phase 2 N=45 Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
Triple Negative Breast Cancer
Primary: Efficacy of Olaparib Alone as Assessed by PFS (Progression-free Survival) Reported as Events Per Month — 0.18 events/month — p=0.0023
Phase 2 N=103 Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids
Internal Hemorrhoids
Primary: Reduction in Swelling — 2.3; 2.0 scores on a scale — p=0.8918
Phase 2 N=55 Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Phase 2 N=25 MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests — 22 Participants
Phase 2 N=8 Trial of IRE in Cholangiocarcinoma
Cholangiocarcinoma
Primary: Number of Patients Experiencing a Clinically Relevant Complications — 1; 7 Participants
Phase 2 N=363 An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Number of Participants Who Meet Response Criteria for Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] at Week 32 — 31; 53; 46; 40 Participants — p=0.0006
Phase 2 N=72 Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Melanoma
Primary: Objective Response Rate (ORR) Per Modified RECIST v1.1 — 3.8; 6.7; 40.0; 46.7 Percentage of Participants
Phase 2 N=197 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis
Primary: The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 — 30.6; 24.0; 26.5; 14.3 Percentage of Participants — p=0.055